In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
ICON integrates Medidata’s Clinical Data Studio into clinical studies
The integration improves decision-making processes and supports AI-driven risk evaluation strategies.
-
Marking the Path Ahead: Integrating Oncology Biomarkers Into Clinical Development' has published
In this article, ICON experts discuss strategies to implement biomarkers in clinical development, saving sponsors time and money while positioning therapies for success.
-
ICON partners with global healthcare leaders to procure renewable power in China
Aligned with ICON's sustainability strategy, this collaboration of 12 companies will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines.
-
The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Partnering for success in early phase clinical development
Early-phase clinical trials serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market. However, these early stages present significant challenges—nearly half of all drugs entering clinical trials do not make it past phase 1. With the average phase 1 trial costing millions of dollars and consuming valuable time, biotechs have little room for error. This article discusses how partnering with a CRO can benefit a small biotech - helping to fill the gaps in knowledge, resources infrastructure.
-
Combination therapies may be the future of oncology – How can we navigate development challenges today?
In this article, ICON experts discuss common ways oncology therapies are combined to achieve synergistic effects, and considerations oncology developers should employ to de-risk combination therapy development.
-
ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
Complexity’s counterpoint: Understanding protocol optimisation
Clinical trial protocols are becoming increasingly complex, with more endpoints and procedures across trial phases and therapeutic areas. ICON experts discuss how protocol optimisation can simplify trial design, accelerate study timelines and drive better outcomes.
-
Why continuity and transparency are key to maximize the value of healthcare data
In today's healthcare landscape, data is a powerful tool for driving informed decisions, enhancing patient care, and shaping strategic business outcomes. However, the real value of healthcare data lies not just in its availability but in its transparency, understanding its origins, methodologies and context. Without clarity, decision-makers risk relying on incomplete or misleading information.
-
Regulatory strategy implications for foetal medicine
In the February edition of TOPRA's Regulatory Rapporteur, ICON summarises the European legislation related to Regulation (EC) 1901/2006 and how it incorporates PIPs but omits the unborn foetus. We also review the guidelines and other application precedents while providing insight into distinctions that may be made by the agency in this matter, as well as highlighting relevant precedents which were identified during this peer reviewed article.
